William Blair analyst Ryan Daniels has maintained their bullish stance on IDXX stock, giving a Buy rating on July 29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors including Idexx Laboratories’ strong financial performance in the second quarter of 2025. The company reported sales and profitability that surpassed consensus expectations, with sales reaching $1,109 million, an 11% increase year-over-year, and adjusted EPS of $3.63, both exceeding market predictions. This strong performance is further supported by the growth in the core companion animal group diagnostics recurring revenue, aligning with management’s optimistic full-year organic growth outlook.
Additionally, management’s decision to raise the 2025 guidance reflects their confidence in continued growth, with expectations for increased reported sales and organic revenue growth. Despite challenges in the end-market, investors are optimistic due to the upcoming product cycle and potential improvements in volumes. The resilience of the pet health market and the aging pet population from the 2020 puppy boom are expected to drive future demand, supporting the Buy rating as the company is well-positioned to meet growth expectations in a challenging environment.
Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, TransMedics Group, and Healthcare Services. According to TipRanks, Daniels has an average return of 4.1% and a 42.22% success rate on recommended stocks.
In another report released on July 29, Morgan Stanley also maintained a Buy rating on the stock with a $628.00 price target.